search
Back to results

Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients

Primary Purpose

Type 2 Diabetes

Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
laparoscopic gastric bypass surgery
laparoscopic adjustable gastric banding
Intensive Medical Management
Sponsored by
Hamilton Health Sciences Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes, Bariatric surgery, Obesity, Laparoscopic gastric bypass, Laparoscopic adjustable gastric banding

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Residents of Southern Ontario, Canada
  • Obese (BMI 30 to < 40 kg/m2) patients who have had type 2 diabetes mellitus for more than 5 years, complicated by at least one of the following situations that persist despite adequate management efforts. The complicating situations are:

    • Severely reduced quality of life as assessed by the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire
    • Metabolic lability/instability, characterized by two or more episodes of severe hypoglycemia (≤ 3mmol/L) or severe hyperglycemia (≥ 25 mmol/L), or two or more hospital visits for diabetic complications over the last year
  • Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by:

    • Retinopathy - a minimum of a three step progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system, or an equivalent progression as certified by an ophthalmologist familiar with diabetic retinopathy or
    • Nephropathy - persistent or progressive macroalbuminuria (>20 mg albumin/mmol creatinine) over at least 12 months (beginning anytime within the past two years) despite the use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or
    • Neuropathy - persistent or progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel or bladder) or persistent or progressing severe peripheral painful neuropathy not responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine)

Exclusion Criteria:

  • Less than 18 years of age or greater than 65 years of age
  • Unable to complete self and interviewer administered questionnaires in English
  • Incapable of providing informed consent
  • Any of the following medical conditions that may be associated with DM:

    • Recent positive history of myocardial infarction or coronary artery bypass graft or percutaneous transluminal angioplasty (less than 6 months)
    • Unstable angina pectoris
    • Recent clinically important ST-T changes on electrocardiogram (ECG) over the past year
    • Cardiac heart failure (New York Heart Association class III and IV; ejection fraction < 50%)
    • Frequent and persistent and unstable supra and ventricular arrhythmias,
    • Brain stroke, transient ischemic attack (TIA),
    • Major diabetic foot infections
    • Autonomic neuropathy resulting in orthostatic dysregulation
  • History of any psychiatric illness that would make the patient a poor candidate for bariatric surgery, as determined by the study psychiatrist
  • If female, pregnant or planning to become pregnant within next year
  • Clinically important cancer history (impact on either lifespan or performance of lap. bariatric surgery)
  • Clinically important abdominal or thoracic surgery that would impact the performance of laparoscopic bariatric procedure
  • Insulin dependence for more than 10 years
  • American Society of Anesthesiologists' classification of 4 or higher
  • Severe gastrointestinal reflux disease with Grade 3 or 4 esophagitis
  • History of pulmonary embolism or deep vein thrombosis
  • Presently taking either high-dose steroids or anticoagulants
  • Advanced nephropathy (Stage 4 or 5 - eGFR less than 30 ml/min)
  • Any other condition that, in the opinion of the study surgeons, would make the patient a poor candidate for bariatric surgery

Sites / Locations

  • St. Joseph's Healthcare

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Intensive Medical Management

Laparoscopic Gastric Bypass

Laparoscopic Adjustable Gastric Band

Arm Description

Medical management of obesity including medication optimization and lifestyle and dietary advice.

Outcomes

Primary Outcome Measures

Diabetic control as assessed by HbA1c

Secondary Outcome Measures

Resolution of diabetes
Improvement in diabetic control and cardio-metabolic profile
Weight loss and decrease in BMI
Reduction in the usage of insulin or other diabetic drugs
Improvement in diabetic complications and end-organ damage
Improvement in health-related quality of life and depression scores
Utilization of resources and productivity losses

Full Information

First Posted
January 26, 2007
Last Updated
April 13, 2016
Sponsor
Hamilton Health Sciences Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00428571
Brief Title
Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients
Official Title
Laparoscopic Bariatric Surgery for Treatment of Type 2 Diabetes in Obese Patients With End Organ Damage: A Prospective Randomized Controlled Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Terminated
Study Start Date
May 2007 (undefined)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hamilton Health Sciences Corporation

4. Oversight

5. Study Description

Brief Summary
A large number of research studies on people who were morbidly obese (extremely overweight), and had bariatric surgery (anti-obesity surgery) have shown that patients who were diabetic before surgery often experienced significant improvement in their diabetes following the surgery. For some patients, blood glucose levels returned to the normal range, and they were able to stop taking all of their diabetes medications. For others, blood glucose levels improved, allowing them to reduce their diabetes medications. This research study is being done to determine whether bariatric surgery can safely provide better control of diabetes symptoms in obese diabetics than continuing medical management (anti-diabetic drugs in combination with diet and lifestyle changes). There are several different types of bariatric surgery currently being used to treat morbid obesity. Two of the most common techniques are gastric bypass and adjustable gastric banding. This study will be comparing these two surgical techniques to treatment with a combination of drugs, diet, and lifestyle changes for control of type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 Diabetes, Bariatric surgery, Obesity, Laparoscopic gastric bypass, Laparoscopic adjustable gastric banding

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intensive Medical Management
Arm Type
Placebo Comparator
Arm Description
Medical management of obesity including medication optimization and lifestyle and dietary advice.
Arm Title
Laparoscopic Gastric Bypass
Arm Type
Active Comparator
Arm Title
Laparoscopic Adjustable Gastric Band
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
laparoscopic gastric bypass surgery
Intervention Description
Laparoscopic Gastric Bypass Surgery
Intervention Type
Procedure
Intervention Name(s)
laparoscopic adjustable gastric banding
Intervention Description
laparoscopic adjustable gastric banding
Intervention Type
Procedure
Intervention Name(s)
Intensive Medical Management
Intervention Description
lifestyle, diet, medication optimization
Primary Outcome Measure Information:
Title
Diabetic control as assessed by HbA1c
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Resolution of diabetes
Time Frame
1 year
Title
Improvement in diabetic control and cardio-metabolic profile
Time Frame
1 year
Title
Weight loss and decrease in BMI
Time Frame
1 year
Title
Reduction in the usage of insulin or other diabetic drugs
Time Frame
1 year
Title
Improvement in diabetic complications and end-organ damage
Time Frame
1 year
Title
Improvement in health-related quality of life and depression scores
Time Frame
1 year
Title
Utilization of resources and productivity losses
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Residents of Southern Ontario, Canada Obese (BMI 30 to < 40 kg/m2) patients who have had type 2 diabetes mellitus for more than 5 years, complicated by at least one of the following situations that persist despite adequate management efforts. The complicating situations are: Severely reduced quality of life as assessed by the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire Metabolic lability/instability, characterized by two or more episodes of severe hypoglycemia (≤ 3mmol/L) or severe hyperglycemia (≥ 25 mmol/L), or two or more hospital visits for diabetic complications over the last year Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by: Retinopathy - a minimum of a three step progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system, or an equivalent progression as certified by an ophthalmologist familiar with diabetic retinopathy or Nephropathy - persistent or progressive macroalbuminuria (>20 mg albumin/mmol creatinine) over at least 12 months (beginning anytime within the past two years) despite the use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or Neuropathy - persistent or progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel or bladder) or persistent or progressing severe peripheral painful neuropathy not responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine) Exclusion Criteria: Less than 18 years of age or greater than 65 years of age Unable to complete self and interviewer administered questionnaires in English Incapable of providing informed consent Any of the following medical conditions that may be associated with DM: Recent positive history of myocardial infarction or coronary artery bypass graft or percutaneous transluminal angioplasty (less than 6 months) Unstable angina pectoris Recent clinically important ST-T changes on electrocardiogram (ECG) over the past year Cardiac heart failure (New York Heart Association class III and IV; ejection fraction < 50%) Frequent and persistent and unstable supra and ventricular arrhythmias, Brain stroke, transient ischemic attack (TIA), Major diabetic foot infections Autonomic neuropathy resulting in orthostatic dysregulation History of any psychiatric illness that would make the patient a poor candidate for bariatric surgery, as determined by the study psychiatrist If female, pregnant or planning to become pregnant within next year Clinically important cancer history (impact on either lifespan or performance of lap. bariatric surgery) Clinically important abdominal or thoracic surgery that would impact the performance of laparoscopic bariatric procedure Insulin dependence for more than 10 years American Society of Anesthesiologists' classification of 4 or higher Severe gastrointestinal reflux disease with Grade 3 or 4 esophagitis History of pulmonary embolism or deep vein thrombosis Presently taking either high-dose steroids or anticoagulants Advanced nephropathy (Stage 4 or 5 - eGFR less than 30 ml/min) Any other condition that, in the opinion of the study surgeons, would make the patient a poor candidate for bariatric surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mehran Anvari, MB BS, PhD
Organizational Affiliation
Centre for Minimal Access Surgery, McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Joseph's Healthcare
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 4A6
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients

We'll reach out to this number within 24 hrs